Original from: 360dx
Diagnostic test maker Technoclone on Tuesday said it has secured US Food and Drug Administration de novo marketing authorization for a test that is used to aid the diagnosis of a rare, life-threatening blood-clotting disorder.
The Vienna-based firm said its Technozym ADAMTS13 Activity ELISA is used for the qualitative determination of von Willebrand factor-cleaving protease ADAMTS13 activity in platelet-poor citrated plasma. The results are used with other clinical and laboratory findings to aid in the diagnosis of thrombotic thrombocytopenic purpura in adult and pediatric patients who are being evaluated for the thrombotic microangiopathy group of rare disorders.
"In line with our commitment to provide ADAMTS13 diagnostics globally, we are excited about this milestone, having the first ADAMTS13 activity test granted with marketing authorization by the FDA," Technoclone CSO Nikolaus Binder said in a statement.
West Chester, Ohio-based DiaPharma Group will be the exclusive US distributor for the assay. DiaPharma is a seller of assay kits, reagents, and instrumentation for clinical and research applications related to bleeding and clotting disorders and liver injury.
Financial and other terms of the deal were not disclosed.
Source: Technoclone Nabs FDA De Novo Authorization for ADAMTS13 Assay
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.